This is reflected in evidence that PI3K/mTOR/AKT signalling is implicated in resistance to CDK4/6 inhibitors, endocrine therapies, HER2-targeted therapy, chemotherapy, PARP inhibitors, radiation and immunotherapy in breast cancer (reviewed by Dong et al. [38]). This evidence concerns the gene MTOR and breast carcinoma.